Fig. 4: In vivo application of the three hit compounds significantly protects RGC somata and axons after traumatic ONC injury.

a Representative OCT images of mouse retina in living animals at 14dpc. GCC: ganglion cell complex, including RNFL, GCL, and IPL layers; indicated as double end red arrows. b Quantification of GCC thickness measured by OCT at 14dpc, represented as percentage of GCC thickness in the ONC eyes compared to the sham contralateral control eyes. n = 10 mice for DMSO, Amo, Desl, and Map; n = 6 mice for ISRIB. c Representative confocal images of peripheral flat-mounted retinas showing surviving RBPMS + (green) RGCs at 14dpc. d Quantification of surviving RGCs at 14dpc, represented as percentage of ONC eyes compared to the sham contralateral control eyes. n = 10 mice for DMSO, Amo, Desl, and Map; n = 6 mice for ISRIB. e Light microscope images of semi-thin transverse sections of ON with PPD staining at 14dpc. f Quantification of surviving RGC axons in ON at 14dpc, represented as percentage of crushed ONs compared to the sham contralateral control ONs. n = 10 mice for DMSO, Amo, Desl, and Map; n = 6 mice for ISRIB. All data in this figure are presented as means ± s.e.m., ****P < 0.0001 ***P < 0.001, **P < 0.01, *P < 0.05, ns: no significance, one-way ANOVA with Dunnett’s multiple comparisons test to compare each treatment to DMSO group. For compound treatment, each eye received intravitreal injection with 2 µl of 2 mM test compounds once and intraperitoneal (i.p.) injection daily (15 mg/kg). Control groups received the same volume of DMSO as vehicle control. Source data are provided as a Source Data file.